Belite Bio, Inc

What they do

Belite Bio is a clinical-stage biopharmaceutical company headquartered in San Diego, California. It focuses on developing novel therapies for metabolic and genetic diseases, with a primary pipeline candidate. The company has a commercial-stage subsidiary in Switzerland and other subsidiaries across the US, Hong Kong, Australia, China, Taiwan, and Japan.

Revenue drivers

• No approved products or commercial revenue — The company does not have any approved products or reported revenue; it has incurred net losses every year from 2021 to 2025.

Recent performance

For fiscal year 2025, Belite Bio reported a net loss of $77.6 million, compared to a net loss of $36.1 million in 2024. Diluted EPS worsened to -$2.31 from -$1.18. Operating cash flow was -$37.0 million in 2025, down from -$29.2 million in 2024. As of December 31, 2025, the company held $352.9 million in cash and equivalents, with total assets of $780.6 million and total liabilities of $10.1 million.

Strategy

Belite Bio is advancing its pipeline through clinical trials, with a focus on regulatory approval in key markets including the US, Europe, and Asia. The company has established operations in multiple countries to support global development and future commercialization. Its strategy includes investing in R&D and clinical programs, which is reflected in growing operating expenses and net losses over the reported period.

Risks

• Clinical-stage risk — The company has no approved products, and its success depends on the successful development and regulatory approval of its pipeline candidates.
• Financing risk — The company has incurred significant net losses and negative operating cash flows, requiring continued external funding to support operations.
• Regulatory risk — Its ability to commercialize products depends on approvals from regulatory agencies such as the FDA, EMA, NMPA, and PMDA, which are uncertain and may face delays.
• Operational risk — The company's operations span multiple countries, exposing it to foreign currency, regulatory, and geopolitical risks.

Outlook

Management's stated direction is to continue advancing its product candidates through clinical development and pursue regulatory approvals globally. The company expects to continue incurring significant R&D and operating expenses as it progresses its pipeline. No revenue is projected in the near term.